DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Oxybutynin (Oxybutynin Chloride) - Published Studies

 
 



Oxybutynin Related Published Studies

Well-designed clinical trials related to Oxybutynin

A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. [2014]

Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial and an assessment of predictive factors. [2012]

Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. [2011.11]

Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (</= 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. [2011.02]

[Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. [2011.01]

Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. [2011.01]

Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. [2011]

Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. [2010.07.06]

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. [2010.05]

Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. [2010]

Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. [2009.11]

Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. [2009.10]

Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. [2009.04]

Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. [2008.09]

Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. [2008.09]

Intravesical Oxybutynin for Children With Poorly Compliant Neurogenic Bladder: A Systematic Review. [2008.07.17]

Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. [2008.05]

A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. [2008.05]

Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. [2008.01]

The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin. [2008.01]

Clinical and urodynamic efficacy of oxybutynin and verapamil in the treatment of nocturnal enuresis after formation of orthotopic ileal neobladders. A prospective, randomized, crossover study. [2008]

Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. [2007.03]

Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. [2007.01]

Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. [2007.01]

The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. [2006.12]

Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. [2006.11]

Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. [2006.09]

Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. [2006.06]

A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. [2006.03]

Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. [2006.03]

Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. [2006.02]

Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. [2005.09]

Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. [2005.09]

Comparison of effects of treatment of primary nocturnal enuresis with oxybutynin plus desmopressin, desmopressin alone or imipramine alone: a randomized controlled clinical trial. [2005.09]

Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. [2005.08]

Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. [2005.07]

Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. [2005.05]

Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. [2005.04.01]

Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. [2005]

Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. [2004.12]

Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. [2004.10]

Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. [2004.10]

A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. [2004.07]

A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. [2004.07]

Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. [2004]

Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. [2003.11]

Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. [2003.08]

Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. [2003.06]

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. [2003.06]

Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. [2003.01]

Transdermal oxybutynin: for overactive bladder. [2003]

A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. [2002.09]

Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. [2002.08]

Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. [2002.05]

Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. [2002.02]

Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). [2002]

Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. [2001.10]

Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. [2001.07]

A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability. [2001.07]

A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. [2001.07]

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. [2001.06]

A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. [2001.05]

Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. [2001.05]

Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. [2001.04]

Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation. [2001.02]

Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. [2001.02]

Interstitial cystitis: bladder training with intravesical oxybutynin. [2000.06]

A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. [2000.05]

Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. [2000.05]

[Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women] [2000.04]

Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial. [2000.03]

Combination therapy of imipramine with oxybutynin in children with enuresis nocturna. [2000]

A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. [1999.10]

Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. [1999.06]

Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. [1999.06]

Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. [1999.03]

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. [1999]

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. [1998.06]

[Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test] [1998.05]

Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. [1998.01]

Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet. [1997.07]

Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. [1997]

Nocturnal enuresis and daytime wetting: a multicentric trial with oxybutynin and desmopressin. [1997]

Efficacy of oxybutynin, pseudoephedrine and indomethacin in the treatment of primary nocturnal enuresis. [1996.04]

Anticholinergic medication for the unstable bladder: prospective trials of imipramine/propantheline versus penthienate and oxybutynin versus penthienate. [1996]

Effect of food on the bioavailability of oxybutynin from a controlled release tablet. [1996]

Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. [1995.07]

Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. [1995.06]

[Topical administration of oxybutynin hydrochloride in women with urge incontinence. Results of a prospective randomized double-blind study] [1995.05]

Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. [1995.04]

[Topical use of oxybutynin hydrochloride in women with urge incontinence] [1994]

Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. [1991.04]

Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. [1990.11]

The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. [1990.06]

Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. [1989.05]

Oxybutynin efficacy in the treatment of primary enuresis. [1988.07]

Well-designed clinical trials possibly related to Oxybutynin

Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial. [2015]

Closeout of the HALT-PKD trials. [2015]

Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease. [2015]

Muco-bioadhesive containing ginger officinal e extract in the management of recurrent aphthous stomatitis: A randomized clinical study. [2015]

Add-on Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. [2015]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017